Interferon beta-1b Treatment in a Korean Girl with Multiple Sclerosis.
- Author:
Hyo Jeong KIM
1
;
Heung Dong KIM
;
Joon Soo LEE
;
Hoon Chul KANG
Author Information
1. Division of Pediatric Neurology, Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea. hipo0207@yuhs.ac
- Publication Type:Case Report
- Keywords:
Multiple sclerosis;
Interferon beta-1b;
Disease modifying therapies
- MeSH:
Adult;
Antibodies, Monoclonal, Humanized;
Asian Continental Ancestry Group;
Child;
Cyclophosphamide;
Humans;
Interferon-beta;
Interferons;
Korea;
Multiple Sclerosis;
Propylene Glycols;
Recurrence;
Sphingosine;
Fingolimod Hydrochloride;
Interferon beta-1b;
Natalizumab
- From:
Journal of the Korean Child Neurology Society
2013;21(1):28-32
- CountryRepublic of Korea
- Language:English
-
Abstract:
Here we report a case of pediatric multiple sclerosis treated with interferon beta-1b. Interferon beta is widely used in adult patients with multiple sclerosis (MS). However, its effects and safety in pediatric patients have not been well established. Although supporting data are limited, the use of disease modifying therapies (DMTs) such as interferon beta-1b is recommended early in treatment of children with MS. Reports of interferon beta treatment in pediatric MS patients in Korea are rare. In this report, we describe a Korean girl who was effectively treated with interferon beta-1b for three years. There were no relapses or serious side effects. Therefore, this report provides evidence supporting the use of interferon beta in pediatric MS patients in Korea and other Asian countries. We also reviewed current medical treatment of MS, including some DMTs and second-line treatment options such as natalizumab and cyclophosphamide, and several new oral agents such as fingolimod.
